In glioma, patients harboring IDH mutations have better prognoses compared to the IDH-wild-type group8,9, and would be the candidate for targeted therapies, such as IDH1-mutant inhibitor, AGI-120 (NCT03564821). This evidence concerns the gene IDH1 and glioma.